These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 8371754)

  • 1. HIV-1 inhibition by a peptide.
    Jiang S; Lin K; Strick N; Neurath AR
    Nature; 1993 Sep; 365(6442):113. PubMed ID: 8371754
    [No Abstract]   [Full Text] [Related]  

  • 2. Effect of amino acid replacements, additions and deletions on the antiviral activity of a peptide derived from the HIV-1 GP41 sequence.
    Jiang S; Lin K
    Pept Res; 1995; 8(6):345-8. PubMed ID: 8838418
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibitors of human immunodeficiency virus type 1 derived from gp41 transmembrane protein: structure--activity studies.
    Kazmierski WM; Hazen RJ; Aulabaugh A; StClair MH
    J Med Chem; 1996 Jul; 39(14):2681-9. PubMed ID: 8709097
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential inhibition of HIV-1 and SIV envelope-mediated cell fusion by C34 peptides derived from the C-terminal heptad repeat of gp41 from diverse strains of HIV-1, HIV-2, and SIV.
    Gustchina E; Hummer G; Bewley CA; Clore GM
    J Med Chem; 2005 Apr; 48(8):3036-44. PubMed ID: 15828842
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A salt bridge between an N-terminal coiled coil of gp41 and an antiviral agent targeted to the gp41 core is important for anti-HIV-1 activity.
    Jiang S; Debnath AK
    Biochem Biophys Res Commun; 2000 Apr; 270(1):153-7. PubMed ID: 10733920
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The inhibitory activity of an HIV type 1 peptide correlates with its ability to interact with a leucine zipper structure.
    Wild C; Greenwell T; Shugars D; Rimsky-Clarke L; Matthews T
    AIDS Res Hum Retroviruses; 1995 Mar; 11(3):323-5. PubMed ID: 7786578
    [No Abstract]   [Full Text] [Related]  

  • 7. Mutations conferring resistance to human immunodeficiency virus type 1 fusion inhibitors are restricted by gp41 and Rev-responsive element functions.
    Nameki D; Kodama E; Ikeuchi M; Mabuchi N; Otaka A; Tamamura H; Ohno M; Fujii N; Matsuoka M
    J Virol; 2005 Jan; 79(2):764-70. PubMed ID: 15613304
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery and optimization of a natural HIV-1 entry inhibitor targeting the gp41 fusion peptide.
    Münch J; Ständker L; Adermann K; Schulz A; Schindler M; Chinnadurai R; Pöhlmann S; Chaipan C; Biet T; Peters T; Meyer B; Wilhelm D; Lu H; Jing W; Jiang S; Forssmann WG; Kirchhoff F
    Cell; 2007 Apr; 129(2):263-75. PubMed ID: 17448989
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Remodeling of gp41-C34 peptide leads to highly effective inhibitors of the fusion of HIV-1 with target cells.
    Otaka A; Nakamura M; Nameki D; Kodama E; Uchiyama S; Nakamura S; Nakano H; Tamamura H; Kobayashi Y; Matsuoka M; Fujii N
    Angew Chem Int Ed Engl; 2002 Aug; 41(16):2937-40. PubMed ID: 12203417
    [No Abstract]   [Full Text] [Related]  

  • 10. Aurothiolates inhibit HIV-1 infectivity by gold(I) ligand exchange with a component of the virion surface.
    Okada T; Patterson BK; Ye SQ; Gurney ME
    Virology; 1993 Feb; 192(2):631-42. PubMed ID: 8421903
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antivirals that target the amino-terminal domain of HIV type 1 glycoprotein 41.
    Gordon LM; Waring AJ; Curtain CC; Kirkpatrick A; Leung C; Faull K; Mobley PW
    AIDS Res Hum Retroviruses; 1995 Jun; 11(6):677-86. PubMed ID: 7576927
    [TBL] [Abstract][Full Text] [Related]  

  • 12. T21/DP107, A synthetic leucine zipper-like domain of the HIV-1 envelope gp41, attracts and activates human phagocytes by using G-protein-coupled formyl peptide receptors.
    Su SB; Gao Jl; Gong Wh; Dunlop NM; Murphy PM; Oppenheim JJ; Wang JM
    J Immunol; 1999 May; 162(10):5924-30. PubMed ID: 10229829
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Temperature-dependent intermediates in HIV-1 envelope glycoprotein-mediated fusion revealed by inhibitors that target N- and C-terminal helical regions of HIV-1 gp41.
    Gallo SA; Clore GM; Louis JM; Bewley CA; Blumenthal R
    Biochemistry; 2004 Jun; 43(25):8230-3. PubMed ID: 15209519
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The stability of the intact envelope glycoproteins is a major determinant of sensitivity of HIV/SIV to peptidic fusion inhibitors.
    Gallo SA; Sackett K; Rawat SS; Shai Y; Blumenthal R
    J Mol Biol; 2004 Jun; 340(1):9-14. PubMed ID: 15184018
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An anti-human immunodeficiency virus multiple antigen peptide encompassing the cleavage region of the env precursor interferes with membrane fusion at a post-CD4 binding step.
    Barbouche R; Decroly E; Kieny MP; Fenouillet E
    Virology; 2000 Jul; 273(1):169-77. PubMed ID: 10891419
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A synthetic peptide from HIV-1 gp41 is a potent inhibitor of virus-mediated cell-cell fusion.
    Wild C; Greenwell T; Matthews T
    AIDS Res Hum Retroviruses; 1993 Nov; 9(11):1051-3. PubMed ID: 8312047
    [No Abstract]   [Full Text] [Related]  

  • 17. Anti-HIV activity of multibranched peptide constructs derived either from the cleavage sequence or from the transmembrane domain (gp41) of the human immunodeficiency virus type 1 envelope.
    Sabatier JM; Mabrouk K; Moulard M; Rochat H; Van Rietschoten J; Fenouillet E
    Virology; 1996 Sep; 223(2):406-8. PubMed ID: 8806580
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Peptide, peptidomimetic and small-molecule drug discovery targeting HIV-1 host-cell attachment and entry through gp120, gp41, CCR5 and CXCR4.
    Kazmierski WM; Kenakin TP; Gudmundsson KS
    Chem Biol Drug Des; 2006 Jan; 67(1):13-26. PubMed ID: 16492145
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessment of the anti-HIV activity of a pine cone isolate.
    Eberhardt TL; Young RA
    Planta Med; 1996 Feb; 62(1):63-5. PubMed ID: 8720390
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structure-activity relationships of an anti-HIV peptide, T22.
    Tamamura H; Murakami T; Masuda M; Otaka A; Takada W; Ibuka T; Nakashima H; Waki M; Matsumoto A; Yamamoto N
    Biochem Biophys Res Commun; 1994 Dec; 205(3):1729-35. PubMed ID: 7811258
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.